Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
PTPN11 mutation
Cancer:
Acute Myelogenous Leukemia
Drug:
Venclexta (venetoclax)
(
Bcl2 inhibitor
) +
mivebresib (ABBV 075)
(
BET inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
ASH 2019
Title:
Biomarker Modulation By Mivebresib (ABBV-075) +/– Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
Published date:
11/06/2019
Excerpt:
Biologic activity was observed particularly in patients treated with MIV-VEN who had SF3B1/U2AF1 or PTPN11 mutations.
DOI:
https://doi.org/10.1182/blood-2019-126854
Trial ID:
NCT02391480
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login